
The Future of Cancer Treatment Takes Shape with Callio Therapeutics’ Revolutionary Approach
Callio Therapeutics, led by CEO Piers Ingram, is innovating cancer treatment with multi-payload antibody-drug conjugates (ADCs). Secured $187 million in Series A funding, primarily from Frazier Life Sciences, emphasizing confidence in their approach. ADCs target malignant cells with precision, potentially reducing side